Novartis announces promising long-term data on Kesimpta for relapsing multiple sclerosis
In a significant revelation, Novartis Pharmaceuticals Corporation has announced the latest findings from the ALITHIOS open-label extension study. The data underscores the sustained efficacy of Kesimpta (ofatumumab), particularly for recently diagnosed, treatment-naïve individuals with relapsing multiple sclerosis (RMS). This group, defined as those who began treatment within three years of their initial diagnosis, experienced substantial […]